(24/7 Market News) Energy and medical listings, mostly biotech and pharma companies, will likely remain the two most dominant trends this week.
Redbox Entertainment Inc. (NASDAQ: RDBX) is running hard in this morning’s premarket; up $4.08 (+30.91%), at $17.28, on 1,595,292 shares traded, so far this morning, after hitting $18.00.
Redbox Entertainment Equity Warrants (NASDAQ: RDBXW) are up even more, percentagewise, more than doubling to $4.87, $2.67 (+121.36%) higher, on 469,556 shares.
Mullen Automotive (NASDAQ:MULN) continues to drift downward and it’s trading at $1.02, down $0.12 (-10.53%) on 2,139,350 shares. The support level around $1 appears to be pretty strong, but, if it can’t hold that, a significant mental barrier will have been breached.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) announced, yesterday, positive initial data from pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in relapsed pediatric low-grade glioma. The topline results from the full FIREFLY-1 trial population are expected in early 2023. It’s up to $11.80, $5.18 (+78.25%) higher, on 2,713,152 share volume.
Bluebird bio Inc (NASDAQ: BLUE) is at $6.22, up $2.49 (+66.76%), on 3,425,540 shares exchanged, after announcing, on Friday, that the FDA Advisory Committee unanimously supports its beti-cel gene therapy for people with beta-thalassemia who require regular red blood cell transfusions and has an August 19, 2022 PDUFA goal date.
Imperial Petroleum Inc (NASDAQ:IMPP) continues to move higher, trading at $0.99, up $0.11 (+12.26%), 10,858,397 shares traded.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.